Specifically, the authors used an established sarcoma mouse model of regressing (R) and progressing (P) tumors [25,26] to test the effect of PD-1 and PD-L1 blockade on tumor/tumor infiltrating lymphocytes (TILs) metabolism. Here, PDCD1 is linked to neoplasm.